[Home] [About us] [Pipeline ] [Alzheimer' Drugs] [Covid Drugs] [Clinical] [Collaboration] [News] [Contact]

Make Alzheimer's a disease of the past

 

A PLATFORM OF INNOVATIVE PRODUCTS


Neuroactiva pipeline


There is no-disease modifying drugs ever been approved for marketing in the United States and all major countries. Researchers continue to find new and better approaches for slowing the progression of Alzheimer’s disease.

NeuroActiva™ has developed a new platform of new drug candidates for treatment of Alzheimer’s and other neurological diseases with innovative mechanism of action. Our flagship drug is called Traneurocin™ or NA-831™. The second drug is called Vineurocin™ or NA-704™.

TRANEUROCIN™ (NA-831™ )

HOW DOES THE DRUG NA-831 ™WORK?

The drug NA-831™is a small molecule drug that can be administered orally. The drug is an endogenous compound i.e. it already exists in the human brain. Basically, the drug is very safe and has no toxicity, suitable for long term treatment and prevention purpose.

The drug NA-831 can easily crosses the blood brain barrier, so only a small dose of the drug is required to be effective. The drug shows the following properties:

  • * NA-831™ exhibits neuroprotection to protect the brain from further damages
  • * The drug exhibits strong neurogenesis, i.e. ability to generate new neurons
  • * It is an endogenous compound (already exists is in the brain)
  • * It has great bioavailability in the body
  • * It is very safe, with no toxicity observed
  • * NA-831™ has been shown to enhance the cognitive functions and improving short term and long term memory of patients in Phase 2A studies
  • * It is available in oral formulation: convenient for patient to take one capsule of 30 mg per day per day.
  • PROOF OF SAFETY AND EFFICACY OF NA-831™ in PHASE 2 CLINICAL

    NeuroActiva has conducted a Randomized Double-Blind Placebo-Controlled Phase 2A Clinical Trial of NA-831 in Patients with MCI and Mild and Moderate Alzheimer’s Disease on 32 patients with mild cognitive impairment and 24 patients with mild and moderate Alzheimer’s disease.

    Based on the Brief Cognitive Rating Scale (BCRS,) the effects of NA-831 were apparent after 14 weeks of treatment (p=0.01), with the significant improvement after 24 weeks in the following areas:

  • * Ability to concentrate
  • * Short term memory,
  • * Long term memory,
  • * Ability to self care,
  • * Orientation
  • * Cognitive functions.

    In addition, patients had significant quality of life improvements, with less fatigue, anxiety, irritability, affective lability, disturbance to waking, daytime drowsiness, headache, and nocturnal sleep.

    NA-831 was well-tolerated with no adverse events or concerning safety signals. In addition, there was a significant improvement in the memory test performance for the Alzheimer’s patients in the study who were administered NA-831 compared to placebo.

    NA-831 showed a significant improvement for patients with mild and moderate AD with the ADAS-Cog score changed of an average of 4.1 as compared to the placebo after 24 weeks of treatment . The Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) showed 82.1% patients improved.

    The topline results of the Phase 2A of NA-831 was presented at the Alzheimer Association International Conference (AAIC) - July 25, 2018 in Chicago and the follow-up results were given at the AAIC, July 17, 2019 in Los Angeles.

  • UPCOMING PHASE 3 CLINICAL TRIALS OF NA-841

    Neuroactiva plans to conduct two Phase 3 programs for NA-831:

    (1) The COGNITION Program for the treatment of 375 patients with mild and moderate Alzheimer’s disease over 12 months. Age group: 65- 80 years of age.

    (2) The PREVENTION Program for the prevention of 550 subjects, asymptomatic from a high risk population over 24 months. Age group: 45-70 years of age.

    These trials follow strict scientific standards and regulatory requirements to protect patients and help produce reliable results.

    Study physicians will review risks and potential benefits with patients and their caregivers before patients are enrolled in the clinical trials.

    The Phase 3 clinical trials of NA-831 have been designed to evaluate its safety and efficacy as required by the US Food and Drug Administration (FDA) and other regulators overseas before being approved for usage and marketing worldwide.

    VINEUROCIN™ (NA-704™ )

    Vineurocin (NA704) can be shown to modulate the aging process in humans. NA-704 can also regulate cell growth and development, especially in nerve cells, as well as cellular DNA synthesis.

    In preclinical studies, NA-704 is able to stimulate regeneration of neurons, outgrowth of electrically active fibers, restoration of neuronal function, and reduction of muscular spasticity.

    NA-704™ is associated with potential reversal of degeneration of neuron axons in certain peripheral neuropathies.

    NA-704™ exhibits neuroprotection and neurogenesis, which has been demonstrated as a strong candidate for treatment of Alzheimer’s disease and other neurological disorders. NA-704 is to be administered intravenously once a week, per prescription of a qualified physician.

    NA-704 has excellent proof of safety in Phase 1 clinical trial. Phase 2 of NA-704 will start in 2020.

    MICROS™ Controlled Release Infusion System

    The MICROS™ Infusion System has been approved by the United Stated Food and Drug Administration (FDA) for marketing in the USA.

    The MICROS Infusion System is a disposable infusion system designed for the intravenous administration of injectable drugs. There are more than 100 injectable drugs can be used with the MICROS for treatment of infectious diseases, cancer chemotherapy and cardiovascular diseases and neurological diseases.

    The MICROS can be prefilled with NA-704 for controlled release of the injectable medication for treatment of Alzheimer's disease and Multiple Sclerosis.

    MICROS is a controlled released infusion system that can be prefilled with a customized dosage of NA-704 to be available as a premixed and ready to use package.

    The NA-704/MICROS infusion system offers an accurate intravenous dosage and is ready to be administered to the patient in a convenient and comfortable setting at home for Alzheimer patients.

    FEATURES & BENEFITS:

    * An advanced infusion system for more than 100 injectable drug formulations for treatment of infectious diseases, cancer chemotherapy, cardiovascular and neurological diseases.

    * The MICROS™ is made with a patented nano-membrane, which provides excellent accuracy and high efficiency exceeding 97%.

    * Ensure aseptic system with built-in nanoscale membrane (50 nanometers) eliminating particulates, bacteria, and endotoxin.

    * A unique disposable infusion system that can be used for multiple doses up to 3 days.

    * A cost-effective drug delivery system that can save a 300 bed hospital more than $200,000 per year in intravenous products.

    For more information about the MICROS™ Infusion System, please visit the MICROS webpage.


    For further information about our platform of productrs, please contact us by completing an Online Contact Form. Thank you.

    Prophylaxis and treatment for Alzheimer's disease and Covid-19:

    • Alzheimer and Covid

      Covid-19 Neuro-invasion

      SARS-CoV-2 can directly invade the CNS. NeuroActiva has developed neuroprotective interventions during the severe acute respiratory syndrome, and provide appropriate rehabilitation measures afterwards.

    • NA-831 capsule

      NA-831 (Traneurocin)

      (NA-831™)(Traneurocin™) is a novel neuroprotective and neurogenesis drug for treatment of Alzheimer's disease which will be in Phase 3 in 2020-2021

    • combination drug

      NA-831™ Drug Therapy

      We have developed drug combination therapy known as Biomedivr™, Neuromedivir™, Dexaneurosone™ Neurosivir™ for the prophylaxis and treatment of Covid-19

    • MICROS Infusion System

      MICROS™ Infusion System

      The MICROS is a FDA approved controlled release infusion system for intravenous administration of injectable drugs, including NA-704 for treatment of neurological diseases.